E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Compensated alcohol-related cirrhosis and portal hypertension |
|
E.1.1.1 | Medical condition in easily understood language |
cirrhosis and portal hypertension |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020786 |
E.1.2 | Term | Hypertension portal |
E.1.2 | System Organ Class | 100000004871 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main purpose of this exploratory study is to investigate the effect of serelaxin (RLX030) infusion on the hepatic and renal circulation in patients with compensated cirrhosis and portal hypertension. Measurements will be acquired non-invasively using magnetic resonance angiography (MRA) (study part A) and more directly via cannulation of the hepatic portal vein during a routine transjugular intrahepatic portosystemic shunt (TIPSS) check procedure (study part B), to determine the acute haemodynamic response to serelaxin (RLX030). |
|
E.2.2 | Secondary objectives of the trial |
-To investigate the change in he blood flow for the hepatic artery (Study Part A (RLX030 treatment group))
-To investigate the change in the blood flow for the superior mesenteric artery (Study Part A (RLX030 treatment group))
-To investigate the change in the blood flow for the descending thoracic aorta (Study Part A (RLX030 treatment group))
-To investigate the change in the blood flow for the portal vein (Study Part A (RLX030 treatment group))
-To investigate the change in the blood flow for total renal arteries ((Study Part A (Terlipressin acetate
treatment group))
-To investigate the change from baseline of the portal vein pressure (PVP) (Study Part B)
-Safety and tolerability of serelaxin (RLX030) |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Part A (Magnetic resonance angiography (MRA))
To investigate whether serelaxin increases the total renal arterial blood flow in patients with cirrhosis and PHT after at least 120 min of infusion (60 min at 80 µg/kg/day and at least 60 min at 30 µg/kg/day).
Part B (direct venous pressure measurement)
To investigate whether serelaxin reduces the portal pressure gradient in patients with cirrhosis, PHT and a TIPSS in situ. |
|
E.3 | Principal inclusion criteria |
Study Parts A and B: -Cirrhosis of alcohol aetiology according to physician’s assessment prior to screening.
Part A: -Cirrhosis with clinical and/or endoscopic evidence of portal hypertension (e.g. oesophageal varices).
Part B: -Cirrhosis with TIPSS in situ and PPG>5mmHg. - Fully functioning TIPSS without variceal filling as confirmed by portography. |
|
E.4 | Principal exclusion criteria |
Study Parts A and B:
-Use of any drug to treat portal hypertension (e.g. vasodilators such as nonselective beta blockers or nitrates) within 1 month prior to screening.
-Decompensated cirrhosis (Child-Pugh score >9 points, and/or ascites requiring diuretics, and/or hepatic encephalopathy) at visit 1.
-Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk.
Part A:
-BMI (weight[kg] / height[m]2) > 40 kg/m2.
-Any contraindication to having an MRI scan.
Other protocol inclusion/exclusion criteria may apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
-Change from baseline of the blood flow for the total renal arteries (Study Part A (RLX030 treatment group))
-Change from baseline of the portal pressure gradient (PPG) (Study Part B) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
-Baseline, after 2-3 hours
-Baseline, after 2 hours |
|
E.5.2 | Secondary end point(s) |
-Change from baseline of the blood flow for the hepatic artery (Study Part A (RLX030 treatment group))
-Change from baseline of the blood flow for the superior mesenteric artery (Study Part A (RLX030 treatment group))
-Change from baseline of the blood flow for the descending thoracic aorta (Study Part A (RLX030 treatment group))
-Change from baseline of the blood flow for the portal vein (Study Part A (RLX030 treatment group))
-Change from baseline of the blood flows (Study Part A (Terlipressin acetate treatment group))
-Change from baseline of the portal vein pressure (PVP) (Study Part B)
-Safety and tolerability of serelaxin (RLX030) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-Baseline, after 2-3 hours
-Baseline, after 2-3 hours
-Baseline, after 2-3 hours
-Baseline, after 2-3 hours
-Baseline, after 2-3 hours
-Baseline, after 2 hours
-Whole duration of the trial |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 7 |